World's 2nd KRAS Inhibitor Approved For Non-Small Cell Lung Cancer With 80% Efficacy!
Significant Improvement In Survival For Pancreatic Cancer Patients! A first-Line NALIRIFOX Regimen To Look Forward To!
More Significant Survival Benefit For Non-Small Cell Lung Cancer Patients Under 55 Years Of Age, Also Using Immunotherapy!
New Research Shows Promise For Bone Marrow Transplant Recipient Patients To Reduce Treatment Side Effects!
New Drug Expected For Patients With Low HER2 Expression, FDA Grants Priority Review Status To Enhertu
Over 30% Of Tumours In Advanced Lung Cancer Patients In Remission With Frontier Drug Teliso-V In Combination With Troche!
